Bitte benutzen Sie diese Referenz, um auf diese Ressource zu verweisen:
doi:10.22028/D291-39780
Titel: | Low Vitamin D Status Predicts Poor Clinical Outcome in Advanced Melanoma Treated With Immune Checkpoint or BRAF/MEK Inhibitors: A Prospective Non-Interventional Side-by-Side Analysis |
VerfasserIn: | Reichrath, Jörg Biersack, Florian Wagenpfeil, Stefan Schöpe, Jakob Pföhler, Claudia Saternus, Roman Vogt, Thomas |
Sprache: | Englisch |
Titel: | Frontiers in oncology |
Bandnummer: | 12 |
Verlag/Plattform: | Frontiers |
Erscheinungsjahr: | 2022 |
Freie Schlagwörter: | BRAF/MEK inhibitor advanced melanoma immune checkpoint inhibitor low vitamin D status melanoma vitamin D vitamin D status |
DDC-Sachgruppe: | 610 Medizin, Gesundheit |
Dokumenttyp: | Journalartikel / Zeitschriftenartikel |
Abstract: | In melanoma and other malignancies, low vitamin D status is associated with increased risk and poor prognosis. However, there are limited data of the impact of 25(OH)D serum concentration (s.c.) on clinical outcome in advanced melanoma. We tested the hypothesis that vitamin D status is predictive of efficacy and safety in patients treated for metastasized melanoma with B-rapidly accelerated fibrosarcoma (BRAF), mitogen-activated protein kinase kinase (MEK), cytotoxic T lymphocyte-associated protein-4 (CTLA-4), and/or programmed cell death protein-1 (PD-1) inhibitors. Severe vitamin D deficiency [defined as 25(OH)D s.c. <10 ng/ml] was associated with markedly reduced overall (OS) and progress-free (PFS) survival, with increased tumor load [TL; measured as s.c. of S100 protein or lactate dehydrogenase (LDH)], and with a trend for higher frequency of adverse events (AEs). An increase in average 25(OH)D s.c. of 1 ng/ml was associated with a 3.9% reduced risk for progressive disease [hazard ratio (HR) = 0.961, p = 0.044], with a reduction of LDH s.c. of 3.86 U/l (p = 0.034, indicating a reduction of TL), and with a trend for reduced frequency of AEs (AE ratio -0.005; p = 0.295). Patients with average 25(OH)D s.c. ≥10 ng/ml and BRAF-mutant melanoma showed a trend for a higher frequency of AEs as compared to individuals with BRAF wild-type melanomas. Our data indicate that vitamin D deficiency is associated with poor clinical outcome in patients treated for metastasized melanoma with BRAF/MEK inhibitors or immunotherapy. Although it needs to be proven in future interventional trials whether optimizing serum 25(OH)D improves clinical outcome in these patients, we recommend that 25(OH)D s.c. should be analyzed and vitamin D deficiency treated in all patients with advanced melanoma. |
DOI der Erstveröffentlichung: | 10.3389/fonc.2022.839816 |
URL der Erstveröffentlichung: | https://doi.org/10.3389/fonc.2022.839816 |
Link zu diesem Datensatz: | urn:nbn:de:bsz:291--ds-397802 hdl:20.500.11880/35843 http://dx.doi.org/10.22028/D291-39780 |
ISSN: | 2234-943X |
Datum des Eintrags: | 16-Mai-2023 |
Fakultät: | M - Medizinische Fakultät |
Fachrichtung: | M - Dermatologie M - Medizinische Biometrie, Epidemiologie und medizinische Informatik |
Professur: | M - Prof. Dr. Thomas Vogt M - Prof. Dr. Stefan Wagenpfeil M - Keiner Professur zugeordnet |
Sammlung: | SciDok - Der Wissenschaftsserver der Universität des Saarlandes |
Dateien zu diesem Datensatz:
Datei | Beschreibung | Größe | Format | |
---|---|---|---|---|
fonc-12-839816.pdf | 2,15 MB | Adobe PDF | Öffnen/Anzeigen |
Diese Ressource wurde unter folgender Copyright-Bestimmung veröffentlicht: Lizenz von Creative Commons